{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:13:08Z","timestamp":1792843988949,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhep.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T04:46:55Z","timestamp":1689569215000},"page":"1302-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Treating NASH by targeting peroxisome proliferator-activated receptors"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-1503","authenticated-orcid":false,"given":"Bart","family":"Staels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5760-1489","authenticated-orcid":false,"given":"Laura","family":"Butruille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.07.004_bib1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.07.004_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.07.004_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.07.004_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2006.10.003","article-title":"PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes","volume":"4","author":"Schuler","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jcsm.12646","article-title":"Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models","volume":"12","author":"Nachit","year":"2021","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jhep.2023.07.004_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2021.02.037","article-title":"Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity","volume":"75","author":"Nachit","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.30049","article-title":"Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study","volume":"68","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib11","doi-asserted-by":"crossref","first-page":"18767","DOI":"10.1016\/S0021-9258(17)32234-2","article-title":"Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids","volume":"269","author":"Rodr\u00edguez","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.07.004_bib12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.07.004_bib13","doi-asserted-by":"crossref","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","article-title":"Loss of hepatic PPAR\u03b1 promotes inflammation and serum hyperlipidemia in diet-induced obesity","volume":"317","author":"Stec","year":"2019","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jhep.2023.07.004_bib14","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1038\/s41598-020-63579-3","article-title":"Hepatocyte-specific deletion of Ppar\u03b1 promotes NAFLD in the context of obesity","volume":"10","author":"R\u00e9gnier","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A\u00a0dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/ATVBAHA.110.220525","article-title":"Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice","volume":"31","author":"Lalloyer","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2023.07.004_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.004_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","article-title":"Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice","volume":"232","author":"Wolf Greenstein","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib21","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jcmgh.2021.01.003","article-title":"Hepatocyte-specific loss of PPAR\u03b3 protects mice from NASH and increases the therapeutic effects of rosiglitazone in the liver","volume":"11","author":"Lee","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib22","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.1203218109","article-title":"Nuclear receptor PPAR\u03b3-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.07.004_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2008.03.003","article-title":"Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27","volume":"7","author":"Matsusue","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1194\/jlr.M046037","article-title":"PPAR\u03b4 activation attenuates hepatic steatosis in Ldlr-\/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity","volume":"55","author":"Bojic","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.07.004_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3858\/emm.2012.44.10.066","article-title":"Peroxisome proliferator-activated receptor \u03b4 agonist attenuates hepatic steatosis by anti-inflammatory mechanism","volume":"44","author":"Lee","year":"2012","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1458-8","article-title":"PPAR\u03b4 attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation","volume":"10","author":"Tong","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2023.07.004_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.07.004_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.31312","article-title":"Hepatic molecular signatures highlight the sexual dimorphism of nonalcoholic steatohepatitis (NASH)","volume":"73","author":"Vandel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41574-021-00538-6","article-title":"Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease","volume":"17","author":"Lefebvre","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gutjnl-2020-323323","article-title":"Integrative study of diet-induced mouse models of NAFLD identifies PPAR\u03b1 as a sexually dimorphic drug target","volume":"71","author":"Smati","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.07.004_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166097","article-title":"PPARs in liver physiology","volume":"1867","author":"Berthier","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2023.07.004_bib33","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1074\/jbc.271.3.1764","article-title":"Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm","volume":"271","author":"Lemberger","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.07.004_bib34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cell.2013.11.034","article-title":"Reprogramming of the circadian clock by nutritional challenge","volume":"155","author":"Eckel-Mahan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.07.004_bib35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2018.06.031","article-title":"Diet-induced circadian enhancer remodeling synchronizes opposing hepatic lipid metabolic processes","volume":"174","author":"Guan","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.07.004_bib36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.febslet.2010.03.019","article-title":"Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride","volume":"584","author":"Chen","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2023.07.004_bib37","first-page":"400","article-title":"Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element","volume":"13","author":"Gervois","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ijo.2011.215","article-title":"Peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) activation advances locomotor activity and feeding daily rhythms in mice","volume":"36","author":"Gutman","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jhep.2023.07.004_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2019.03.020","article-title":"The circadian clock and liver function in health and disease","volume":"71","author":"Mukherji","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","article-title":"Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial","volume":"35","author":"Ezpeleta","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00125-022-05813-3","article-title":"Timing of physical activity in relation to liver fat content and insulin resistance","volume":"66","author":"van der Velde","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.07.004_bib42","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.tem.2022.07.001","article-title":"Immune-metabolic interactions in homeostasis and the progression to NASH","volume":"33","author":"Hoogerland","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib43","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42255-019-0076-1","article-title":"Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution","volume":"1","author":"Haas","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","article-title":"Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C\/EBP-beta complex formation","volume":"101","author":"Kleemann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2023.07.004_bib45","doi-asserted-by":"crossref","first-page":"16154","DOI":"10.1074\/jbc.M400346200","article-title":"Global suppression of IL-6-induced acute phase response gene expression after chronic in\u00a0vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate","volume":"279","author":"Gervois","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.07.004_bib46","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jhep.2005.10.033","article-title":"Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates","volume":"44","author":"Shiri-Sverdlov","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib47","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.07.004_bib49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1210\/me.2014-1383","article-title":"Ketone body therapy protects from lipotoxicity and acute liver failure upon ppar\u03b1 deficiency","volume":"29","author":"Pawlak","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib50","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.07.004_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","article-title":"PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties","volume":"6","author":"Bouhlel","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1101\/gad.312355.118","article-title":"PPAR\u03b3 is a nexus controlling alternative activation of macrophages via glutamine metabolism","volume":"32","author":"Nelson","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhep.2023.07.004_bib53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/toxsci\/kfn142","article-title":"Ligand activation of peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression","volume":"105","author":"Shan","year":"2008","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2023.07.004_bib54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cmet.2020.10.026","article-title":"The power of plasticity\u2014metabolic regulation of hepatic stellate cells","volume":"33","author":"Trivedi","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/mmr.2014.2846","article-title":"microRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor \u03b3","volume":"11","author":"Li","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib56","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.07.004_bib57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/gast.2003.50015","article-title":"Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells","volume":"124","author":"Hellemans","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.004_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2045-3701-2-34","article-title":"GW501516-activated PPAR\u03b2\/\u03b4 promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation","volume":"2","author":"Kostadinova","year":"2012","journal-title":"Cell Biosci"},{"key":"10.1016\/j.jhep.2023.07.004_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166235","article-title":"Nuclear receptors in liver fibrosis","volume":"1867","author":"K\u00f6nigshofer","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2023.07.004_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasar\u00edn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.07.004_bib61","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/labinvest.2012.103","article-title":"Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture","volume":"92","author":"Francque","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2023.07.004_bib62","article-title":"Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD","volume":"4","author":"van der Graaff","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib63","unstructured":"Rautou P-E, Wettstein G, Bedossa P, Cooreman M, Baudin M, Huot-Marchand P, et\u00a0al. Liver sinusoidal endothelial cell (lsec) capillarization in nash and its evolution following lanifibranor treatment: an exploratory study of the native clinical trial\u00a02021."},{"key":"10.1016\/j.jhep.2023.07.004_bib64","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","article-title":"Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease","volume":"20","author":"Bassegoda","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib65","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2020.10.003","article-title":"Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis","volume":"74","author":"Ferrusqu\u00eda-Acosta","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/apt.17046","article-title":"Review article: vascular effects of PPARs in the context of NASH","volume":"56","author":"Guix\u00e9-Muntet","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.07.004_bib67","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/01.CIR.0000097003.49585.5E","article-title":"Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia","volume":"108","author":"Tao","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.07.004_bib68","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCRESAHA.108.176339","article-title":"Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet","volume":"103","author":"Beyer","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jhep.2023.07.004_bib69","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/00005344-200212000-00003","article-title":"Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells","volume":"40","author":"Martin-Nizard","year":"2002","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jhep.2023.07.004_bib70","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cvr\/cvs362","article-title":"Protective role of vascular smooth muscle cell PPAR\u03b3 in angiotensin II-induced vascular disease","volume":"97","author":"Marchesi","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jhep.2023.07.004_bib71","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cmet.2012.08.011","article-title":"Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPAR\u03b3 and RhoA\/Rho-kinase","volume":"16","author":"Pelham","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib72","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib73","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib74","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2018.03.018","article-title":"Beneficial effects of the peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension","volume":"188","author":"Tsai","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2023.07.004_bib75","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106638","article-title":"Anti-inflammatory effects and improved metabolic derangements in ob\/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity","volume":"187","author":"Marques","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhep.2023.07.004_bib77","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.07.004_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1160\/TH13-01-0075","article-title":"Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology","volume":"110","author":"Morange","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhep.2023.07.004_bib79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.26510","article-title":"Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"59","author":"Verrijken","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.26588","article-title":"Prothrombotic factors and nonalcoholic fatty liver disease: an additional link to cardiovascular risk?","volume":"59","author":"Barrera","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib81","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib82","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib83","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2023.07.004_bib84","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1182\/bloodadvances.2020002493","article-title":"Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPAR\u03b1-dependent manner","volume":"4","author":"Yeung","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhep.2023.07.004_bib85","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00041433-199912000-00011","article-title":"Fibrates, dyslipoproteinaemia and cardiovascular disease","volume":"10","author":"Watts","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jhep.2023.07.004_bib86","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/toxsci\/kfi273","article-title":"Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver","volume":"88","author":"Cariello","year":"2005","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2023.07.004_bib87","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1152\/physiolgenomics.00100.2011","article-title":"Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice","volume":"43","author":"Lu","year":"2011","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jhep.2023.07.004_bib88","series-title":"Mouse models of nonalcoholic steatohepatitis towards optimization of their relevance to human nonalcholic steatohepatitis","first-page":"2257","author":"Farrell","year":"2019"},{"key":"10.1016\/j.jhep.2023.07.004_bib89","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2023.07.004_bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/toxsci\/kfm206","article-title":"The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha","volume":"101","author":"Yang","year":"2008","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2023.07.004_bib91","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jhep.2023.07.004_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib94","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1478-3231.2006.01265.x","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver","volume":"26","author":"Harano","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.07.004_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1746.2011.06939.x","article-title":"Peroxisome proliferator-activated receptor-\u03b1 agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis","volume":"27","author":"Larter","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib96","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep4.1558","article-title":"The selective peroxisome proliferator-activated receptor gamma modulator CHS-131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis","volume":"4","author":"Perakakis","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.07.004_bib97","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2023.07.004_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","author":"Lefere","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2023.07.004_bib100","first-page":"S0168","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","author":"Tacke","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib101","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.07.004_bib102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/jc.2009-1487","article-title":"Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome","volume":"95","author":"Belfort","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib103","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.jhep.2023.07.004_bib105","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.07.004_bib106","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/ijms20030706","article-title":"Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment","volume":"20","author":"Yokote","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.07.004_bib107","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.07.004_bib108","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","article-title":"PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein","volume":"50","author":"Maeda","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.07.004_bib109","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.004_bib110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib111","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fendo.2018.00473","article-title":"Deciphering the roles of PPAR\u03b3 in adipocytes via dynamic change of transcription complex","volume":"9","author":"Ma","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2023.07.004_bib112","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2036.2010.04405.x","article-title":"Pioglitazone in the treatment of NASH: the role of adiponectin","volume":"32","author":"Gastaldelli","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.07.004_bib113","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib114","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib115","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.07.004_bib116","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.004_bib117","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib118","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib119","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib120","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.07.004_bib121","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.07.004_bib122","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcmgh.2018.09.017","article-title":"Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism","volume":"7","author":"McCommis","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib123","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jhep.2023.07.004_bib124","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.jhep.2023.07.004_bib126","series-title":"A\u00a0phase 2b, prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of saroglitazar magnesium in subjects with nonalcoholic steatohepatitis and fibrosis","year":"2023"},{"key":"10.1016\/j.jhep.2023.07.004_bib127","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.07.004_bib128","series-title":"A\u00a0phase 2, double-blind, randomized, placebo-controlled study followed by an open-label extension period to evaluate the activity of seladelpar in subjects with nonalcoholic steatohepatitis (NASH)","year":"2022"},{"key":"10.1016\/j.jhep.2023.07.004_bib129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.004_bib130","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.07.004_bib131","first-page":"72","article-title":"The dual PPAR\u03b1\/\u03b4 agonist elafibranor did not achieve resolution of NASH without worsening of fibrosis in adult patients with non-alcoholic steatohepatitis and significant fibrosis","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib132","series-title":"24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)","article-title":"A\u00a0randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept","year":"2021"},{"key":"10.1016\/j.jhep.2023.07.004_bib133","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib134","series-title":"LO5: efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis: Results from the phase 2b,randomized, double-blind","author":"Loomba","year":"2022"},{"key":"10.1016\/j.jhep.2023.07.004_bib135","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"S1","key":"10.1016\/j.jhep.2023.07.004_bib136","first-page":"5006","article-title":"Efruxifermin (EFX) in nonalcoholic steatohepatitis with fibrosis: results from A randomized, double-blind, PLACEBO-controlled, phase 2b trial (harmony) - abstract 5006","volume":"76","author":"Harrison","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.004_bib137","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib138","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.biochem.74.082803.133329","article-title":"Biochemistry of mammalian peroxisomes revisited","volume":"75","author":"Wanders","year":"2006","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jhep.2023.07.004_bib139","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.53.1.14","article-title":"Peroxisome proliferator activated receptor-alpha expression in human liver","volume":"53","author":"Palmer","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2023.07.004_bib140","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1158\/0008-5472.CAN-04-0322","article-title":"Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha","volume":"64","author":"Cheung","year":"2004","journal-title":"Cancer Res"},{"issue":"Pt 3","key":"10.1016\/j.jhep.2023.07.004_bib141","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1042\/bj3320689","article-title":"Molecular basis of non-responsiveness to peroxisome proliferators: the Guinea-pig PPARalpha is functional and mediates peroxisome proliferator-induced hypolipidaemia","volume":"332","author":"Bell","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2023.07.004_bib142","doi-asserted-by":"crossref","first-page":"31521","DOI":"10.1074\/jbc.M103306200","article-title":"Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson","volume":"276","author":"Lawrence","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.07.004_bib143","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis","volume":"47","author":"Balas","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib144","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.07.004_bib145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.07.004_bib146","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib147","first-page":"223","article-title":"Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial","volume":"11","author":"Portillo-Sanchez","year":"2019","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.jhep.2023.07.004_bib148","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jhep.2023.07.004_bib149","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib150","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.07.004_bib151","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.07.004_bib152","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.07.004_bib153","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.07.004_bib154","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.118.034763","article-title":"Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone","volume":"138","author":"Young","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.07.004_bib155","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","article-title":"Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus","volume":"119","author":"van der Meer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.07.004_bib156","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2337\/dc17-0078","article-title":"Pioglitazone improves left ventricular diastolic function in subjects with diabetes","volume":"40","author":"Clarke","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.07.004_bib157","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.amjmed.2017.04.010","article-title":"Diabetes mellitus and heart failure","volume":"130","author":"Lehrke","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib158","first-page":"S722","article-title":"The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change","volume":"77","author":"Cooreman","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 8A","key":"10.1016\/j.jhep.2023.07.004_bib159","doi-asserted-by":"crossref","first-page":"111S","DOI":"10.1016\/j.amjmed.2003.09.018","article-title":"Considerations for management of fluid dynamic issues associated with thiazolidinediones","volume":"115","author":"Hollenberg","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib160","first-page":"3","article-title":"Bone: PPAR\u03b3 controls marrow adiposity","volume":"14","author":"Bradley","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2023.07.004_bib161","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.exphem.2005.05.003","article-title":"Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation","volume":"33","author":"Nagasawa","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jhep.2023.07.004_bib162","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.stemcr.2017.03.008","article-title":"In\u00a0Vivo RNAi screen unveils PPAR\u03b3 as a regulator of hematopoietic stem cell homeostasis","volume":"8","author":"Sertorio","year":"2017","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jhep.2023.07.004_bib163","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jhep.2023.07.004_bib164","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/HYPERTENSIONAHA.110.164590","article-title":"Peroxisome proliferator-activated receptor \u03b2\/\u03b4 activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition","volume":"57","author":"Liu","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jhep.2023.07.004_bib165","first-page":"3930","article-title":"Nuclear receptors PPARbeta\/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart","volume":"117","author":"Burkart","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.07.004_bib166","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jhep.2023.07.004_bib167","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1073\/pnas.0711875105","article-title":"PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis","volume":"105","author":"Barish","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2023.07.004_bib168","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib169","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.004_bib170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc07-1868","article-title":"Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial","volume":"31","author":"Dagenais","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.07.004_bib171","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaneurol.2019.0079","article-title":"Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial","volume":"76","author":"Spence","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jhep.2023.07.004_bib172","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jhep.2023.07.004_bib173","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.004_bib174","article-title":"The liver and the cardiovascular system: two of a kind?","volume":"10","author":"Francque","year":"2021","journal-title":"J\u00a0Am\u00a0Heart Assoc"},{"key":"10.1016\/j.jhep.2023.07.004_bib175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and mechanisms of nonalcoholic fatty liver disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jhep.2023.07.004_bib176","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:51:18Z","timestamp":1759175478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823049802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":176,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0168827823049802"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating NASH by targeting peroxisome proliferator-activated receptors","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}